Navigation Links
Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
Date:10/17/2007

um) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients for a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed an oral formulation of the active ingredient in Ganite that is currently undergoing initial clinical trials as a potential treatment for diseases associated with accelerated bone loss. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... FORT WORTH, Texas , May 28, 2015 /PRNewswire/ ... defines and segments the concerned market with analysis and ... million in 2014 and is estimated to reach $1,177.8 ... 2014 to 2019. Browse through the TOC ... the industry trends and segments, with help of various ...
(Date:5/28/2015)... 28, 2015  Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ... Alan Shortall , will present at the Jefferies 2015 Global ... 3:00 p.m. ET on Monday, June 1, 2015. ... as a "live" listen only Webcast. To listen, please go ... also be available for those unable to listen live. ...
(Date:5/28/2015)... May 26, 2015 Research and Markets( ... "2015 Strategies in the US Ancillary Hospital ... report to their offering. This new ... analysis of the diagnostic testing markets outside the ... report includes analysis of the market dynamics, size, ...
Breaking Medicine Technology:Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 2Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 3Strategies in the US Ancillary Hospital Locations (ERs, ORs, ICUs) Diagnostic Testing Market 2015-2020 2
... Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ) ... develops new uses for previously approved drugs and new ... PTO notification of the allowance of two important U.S. ... class of compounds that combine elements of diketopiperazines (same ...
... Reportlinker.com announces that a new market research ... X-ray Equipment - Top 5 ... This package contains top ... American countries: United States, Mexico, Canada, Colombia, ...
Cached Medicine Technology:Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases 2X-ray Equipment - Top 5 American Markets 2
(Date:5/28/2015)... Lakes, FL (PRWEB) May 28, 2015 Nidra ... is incredibly gentle on the body. A non-addictive supplement, Nidra ... this blend of natural ingredients will leave users with a ... holistic system of care , Ayurveda, which translates as the ... more than 5,000 years ago and is a holistic system ...
(Date:5/28/2015)... Ticket Down is a reputable source of ... Mexico and Argentina in early September. , Two of ... on the pitch at AT&T Stadium in Arlington/Dallas, TX. Mexico ... friendly on Tuesday, September 8th at 9 p.m. The match ... world including some of the most loved players in the ...
(Date:5/28/2015)... CA (PRWEB) May 28, 2015 ... clinic will now be offering Echocardiography Examinations to ... be performed by renowned Qualified Medical Examiner and ... The echocardiography test is a non-invasive and cost-effective ... who are critically ill or have undergone surgery. ...
(Date:5/28/2015)... 28, 2015 According to a ... ), the shoulder reconstruction device market, was the ... & joint market in 2014. This trend is ... in the U.S. due to increased surgeon experience ... resulting in greater patient outcomes. Therefore, surgeons are ...
(Date:5/28/2015)... 2015 Dr. Paul Vitenas, one of ... announced that the new Houston Surgery Center he recently ... Accreditation of Ambulatory Surgery Facilities awarded this accreditation to ... , According to Dr. Vitenas, the certificate was given ... a Class C ambulatory surgery facility. This certification means ...
Breaking Medicine News(10 mins):Health News:Ayurveda Herba Corp’s Revolutionary Herbal Sleep Supplement is Now Available from Amazon.com 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3Health News:Healthpointe Is Now Offering Echocardiography Examinations at the Anaheim Clinic. 2Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 2Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 3Health News:Dr. Paul Vitenas’ New Houston Surgery Center Receives AAAASF Accreditation 2
... Indian state of Tamilnadu has launched a free nutritional ... World Food Programme of the United Nations (UNWFP) ... this scheme called Nutriplus. ,Gian Pietro ... to the government of Tamilnadu signed on Friday a ...
... to set up quality hospitals on the model of ... in Patna//, Raipur, Bhopal, Bhubaneshwar, Jodhpur and Rishikesh under ... for Health and Family Welfare Anbumani Ramadoss has said. ... by some members of the Rajya Sabha, the upper ...
... The Animal Welfare Board of India (AWBI) has started a ... a new anti-rabies// oral bait vaccine that will be fed ... stray and community dogs are being sterilized in India, says ... is estimated at nearly 20 million. ,Headquartered in ...
... writes on National Health Services called Frontpoint Systems ... President of the Royal College of Obstetricians & ... overseas medical graduates. ,The site highlights ... about medical politics in the UK has published ...
... has long been known to give a boost to the ... good health//. Now, a Christchurch researcher has delved into the ... apart from maintaining the body’s cells, Vitamin C may also ... Radical Research Group, along with a team from the Angiogenesis ...
... New Zealand researchers claimed Friday that vitamin C was vital ... making chemotherapy treatment more effective//. ,Dr Margret Vissers, from ... for the first time that vitamin C was a vital ... to be taken when people had a cold. ...
Cached Medicine News:Health News:More Evidence of Racial Discrimination in the NHS 2Health News:Vitamin C Could Help in Curbing Cancer 2
... Smoothie is deliciously refreshing scrub ... the use of a gentle ... exfoliate the skin to restore ... irritation. This light chemical peel ...
... of Salicylic Acid Exfoliator 30% and ... be used by Physicians or Skin ... for intense skin peeling and exfoliation ... of skin correction. This kit works ...
... Fat Harvest, Wash & Transfer System is ... make fat transfer procedures simpler for the ... the need for an office-based technique. LipiVage™ ... is no longer a need to centrifuge, ...
... and Zyplast® injectable collagen implants have set ... facial lines, wrinkles and scars and in ... skins natural collagen, require minimal procedure time, ... one million people worldwide have been treated ...
Medicine Products: